MRNA
Moderna
$59.35
▼ 7.2%Updated Today 7:15 PM ET
▲ Up 151.8% over the last 12 months
Market Cap
$25.38B
P/E
—
Forward P/E (est.)
—
ROE
-36.7%
Revenue Growth
-30.0%
EPS Growth
—
Profit Margin
-143.6%
FCF Yield
-13.6%
Debt / Equity
0.07x
ROIC
-30.0%
Interest Coverage
—
Current Ratio
2.41x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
17/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what MRNA's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. MRNA trades near $59.35, above its 50-day average ($50.20) and 200-day average ($39.22). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 76 it is overbought — the recent rally is stretched and can cool off.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. MRNA's is $3.94 (~6.6% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month MRNA found buyers near $43.90 (support) and sellers near $67.74 (resistance); its 52-week range is $22.28–$67.74. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 3.4× the 20-day average — heavier than usual, which adds conviction to the move. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Moderna (MRNA) is a large-cap company in the Biotechnology industry, part of the Health Care sector of the S&P 500, with a market value around $25.38B.
In its latest reported year it generated about $1.94B in revenue and posted a net loss of $2.82B.
Our model rates MRNA Weak (17/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
-43.0%
Revenue moved from $18.47B in 2021 to $1.94B in 2025, a -43.0% compound annual growth rate. The most recent year declined 30.0% year over year. Shrinking revenue is worth a closer look — is it cyclical or structural?
Gross Margin
35.0%
Operating Margin
-158.1%
Net Margin
-145.2%
ROE
-36.7%
Moderna keeps about -143.6% of each sales dollar as net profit, with a 35.0% gross margin and -158.1% operating margin. Return on equity is -36.7% and return on invested capital about -30.0%. The company is currently unprofitable on a net basis.
Total Debt
$590.00M
Net Debt
-$1.32B
Net cash position
Net Debt / EBITDA
—
Debt / Equity
0.07x
Leverage: debt-to-equity is 0.1x, with a current ratio of 2.4x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $590.00M of total debt against $1.91B of cash.
Operating CF
-$1.87B
Free Cash Flow
-$2.06B
FCF Margin
-106.2%
In the latest year Moderna produced about -$1.87B of operating cash flow but negative free cash flow as it invested heavily. That is a free-cash-flow yield of about -13.6% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
—
P/S
11.31x
P/B
1.54x
EV / EBITDA
—
MRNA trades at n/a trailing earnings, 11.3x sales, and 1.5x book value. With no positive trailing earnings, value it on sales, cash flow, or growth rather than P/E.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How MRNA stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), MRNA ranks #59 of 59 by our overall rating.
P/E vs sector
—
median 25.4x
ROE vs sector
-36.7%
median 14.9%
Growth vs sector
-30.0%
median 7.9%
Sector rank
#59
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$2.04 – $3.41
vs. $59.35 today · expected CAGR -49% – -44%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $2.00B | $2.06B | $2.12B | $2.19B | $2.25B |
| Net income | $60.07M | $61.87M | $63.73M | $65.64M | $67.61M |
| EPS | $0.15 | $0.16 | $0.16 | $0.17 | $0.17 |
| Share price (low) | $1.82 | $1.87 | $1.93 | $1.99 | $2.04 |
| Share price (high) | $3.03 | $3.12 | $3.21 | $3.31 | $3.41 |
| CAGR (low–high) | -97% / -95% | -82% / -77% | -68% / -62% | -57% / -51% | -49% / -44% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for MRNA:
- A conservative balance sheet (debt/equity 0.1x) lowers risk.
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against MRNA:
- Revenue growth is slow/negative (-30.0%), limiting the upside engine.
- Thin net margins (-143.6%) leave little room for error.
- Limited free cash flow at today's price.
- Our model's overall read is Weak (17/100).
Growth risk — sluggish revenue (-30.0%) leaves little margin for execution missteps.
Margin risk — thin profitability (-143.6%) is vulnerable to cost or pricing pressure.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen weakly: Moderna is a large-cap health care business with shrinking revenue, with modest profitability, and a sound balance sheet. It trades at n/a earnings, which our model scores Weak (17/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.